• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Sagaliam Acquisition Corp.

    4/24/23 6:15:12 AM ET
    $SAGA
    Blank Checks
    Finance
    Get the next $SAGA alert in real time by email
    0001855351 false 0001855351 2023-04-21 2023-04-21 0001855351 SAGAU:UnitsEachConsistingOfOneShareOfClassCommonStockParValue0.0001PerShareAndRightMember 2023-04-21 2023-04-21 0001855351 SAGAU:ClassCommonStockIncludedAsPartOfUnitsMember 2023-04-21 2023-04-21 0001855351 SAGAU:RightsIncludedAsPartOfUnitsMember 2023-04-21 2023-04-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): April 21, 2023

     

    Sagaliam Acquisition Corp.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41182   86-3006717

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    Barry Kostiner

    1800 Avenue of the Stars, Suite 1475

    Los Angeles, CA 90067

    (Address of principal executive offices, including zip code)

     

    Registrant’s telephone number, including area code: (213) 616-0011

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
             
    Units, each consisting of one share of Class A common stock, par value $0.0001 per share, and right   SAGAU   The Nasdaq Stock Market LLC
    Class A common stock included as part of the units   SAGA   The Nasdaq Stock Market LLC
    Rights included as part of the units   SAGAR   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 8.01 Other Events.

     

    Membership Interest Purchase Agreement

     

    On March 23, 2023, GLD Sponsor Member, LLC, a Delaware limited liability company (the “Seller”), entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) with BN Holdings Trust, a Nevada Trust (“BN Holdings Trust”) and Sagaliam Sponsor, LLC (the “Sponsor”), pursuant to which BN Holdings Trust agreed to purchase all of the issued and outstanding equity interests in the Sponsor from the Seller, which constitutes 100% of the membership interests in the Sponsor. The consummation of the transactions contemplated by the Purchase Agreement (the “Closing”) is expected to take place at 10:00 am, New York time, on or before April 28, 2023.

     

    There are a number of conditions precedent to the Closing including the delivery of an amended letter agreement, pursuant to which Sagaliam Acquisition Corp. (the “Company”) and EF Hutton, as underwriter to the Company, will consent to the transfer of certain Class A units and Class B Shares from the Sponsor to certain individuals and entities as listed in the Purchase Agreement. The Purchase Agreement also requires (i) the delivery of a release in favor of the Seller by the Sponsor and certain third parties, (ii) the delivery of indemnification and hold harmless agreements between BN Holdings Trust and certain third parties, including the current directors of the Company, (iii) the assumption by BN Holdings Trust of certain obligations of the Sponsor and the Company, each of which are to be paid as of the closing date of a business combination for the Company, (iv) the maintenance of directors’ and officers’ liability insurance and (v) the resignation of the current officers of the Sponsor.

     

    Business Combination Extension

     

    On April 21, 2023, the Company notified Continental Stock Transfer & Trust Company that it was exercising its option to extend the time available to consummate a business combination by an additional one month, thereby extending the de-SPAC deadline from April 23, 2023 to May 23, 2023. Furthermore, in accordance with the Investment Management Trust Agreement between the Company and Continental Stock Transfer & Trust Company, dated December 20, 2021, the date by which the Company has to complete its business combination has been extended by the Company from April 23, 2023 to May 23, 2023 (the “Extension”) by depositing $57,380.22 into the trust account for its public stockholders. The Extension is the fifth of ten one-month extensions permitted under the Company’s governing documents and provides the Company with additional time to complete its business combination.

     

    2

     

     

    Disclaimer

     

    This Current Report on Form 8-K is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy any securities or the solicitation of any vote in any jurisdiction pursuant to the proposed transactions or otherwise, nor shall there be any sale, issuance or transfer or securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

     

    INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION (“SEC”) OR ANY OTHER REGULATORY AUTHORITY NOR HAS ANY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE PROPOSED TRANSACTIONS OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED HEREIN. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

     

    Forward Looking Statements

     

    The disclosure herein includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations, Company’s ability to enter into a definitive business combination agreement and Company’s ability to obtain the financing necessary to consummate the potential business combination transaction. These statements are based on various assumptions and on the current expectations of Company’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Company. These forward-looking statements are subject to a number of risks and uncertainties, including: Company’s ability to enter into a definitive agreement with respect to the proposed business combination or consummate a transaction; the risk that the approval of the stockholders of Company for the potential transaction is not obtained; failure to realize the anticipated benefits of the potential transaction, including as a result of a delay in consummating the potential transaction or difficulty in integrating the businesses of Company; the amount of redemption requests made by Company’s stockholders and the amount of funds remaining in Company’s trust account after satisfaction of such requests; those factors discussed in Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 under the heading “Risk Factors,” and other documents of Company filed, or to be filed, with the SEC. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Company presently does not know or that Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Company’s expectations, plans or forecasts of future events and views as of the date hereof. Company anticipates that subsequent events and developments will cause Company’s assessments to change. However, while Company may elect to update these forward-looking statements at some point in the future, Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Company’s assessments as of any date subsequent to the date of this disclosure statement. Accordingly, undue reliance should not be placed upon the forward-looking statements.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    The following exhibit is filed herewith:

     

    Exhibit No.   Description of Exhibits
         
    99.1   Company Press Release, dated April 21, 2023
         
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    3

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Sagaliam Acquisition Corp.
       
      By: /s/ Barry Kostiner
      Name: Barry Kostiner
      Title: Chief Executive Officer

     

    Dated: April 24, 2023

     

    4

     

    Get the next $SAGA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SAGA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SAGA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sagaliam Acquisition Corp Launches Improved IPF Formula with Vitamin C in Pill and Lozenge Form and Addition of New Slimming Neutraceutical

    BAYTOWN, TX / ACCESSWIRE / May 1, 2024 / Sagaliam Acquisition Corp ("SAGA", the "Company") (NASDAQ:SAGA) announced today that Virogentics, Inc., a wholly owned subsidiary of SAGA ("VIRO"), and the Bulgarian product development team, headed by Dr. Lachezar Ivanov and Harry Zhabilov, CSO, have developed a new IPF formula which combines a Vitamin C component with the existing patented compound. This product will be marketed as IPF Immune+ with Vit C. In addition, this new product will be available in both pill and lozenge form providing convenience and a more effective delivery for the users. The team has also begun production of a new slimming formula which will be added to the VIRO nutraceuti

    5/1/24 8:30:00 AM ET
    $SAGA
    Blank Checks
    Finance

    Sagaliam Acquisition Corp. Announces Novation Agreement with Enzolytics, Inc.

    NEW YORK, NY / ACCESSWIRE / April 26, 2024 / Sagaliam Acquisition Corp. ("SAGAU", "SAGA", SAGAR") (the "Company") announced that Sagaliam entered into a Novation Agreement with Enzolytics, Inc. (OTC:ENZC), Biogenysis, Inc. (BGEN), and Virogentics, Inc. (VIRO) (together the "Parties"). ​Under this restructured agreement SAGA retains 100% ownership of VIRO, ITV-1, the nutraceutical products and license along with VIRO's other assets. This agreement transferred ownership of Biogenysis, Inc. ("BGEN") and it's IP, patents and associated asset being developed back to ENZC in exchange for a reduction of the price from $450,000,000 to $290,000,000 with the dividend of the purchase shares to come dir

    4/26/24 8:00:00 AM ET
    $SAGA
    Blank Checks
    Finance

    SAGALIAM ACQUISITION CORP. ANNOUNCES DELISTING OF COMMON SHARES FROM NASDAQ

    New York, NY, March 07, 2024 (GLOBE NEWSWIRE) -- Sagaliam Acquisition Corp. (NASDAQ: "SAGAU", "SAGA", SAGAR") (the "Company") received a Nasdaq Hearing Withdrawal letter ("Notice") from the Listing Qualifications staff of the Nasdaq Stock Market LLC ("Nasdaq") on March 6, 2024. On May 26, 2023, Staff notified the Company that the market value of its listed securities had been below the minimum $50,000,000 required for continued listing as set forth in Listing Rule 5450(b)(2)(A) for the previous 30 consecutive trading days.1 Therefore, in accordance with Listing Rule 5810(c)(3)(C), the Company was provided 180 calendar days, or until November 22, 2023 to regain compliance with the Rule. O

    3/7/24 9:35:00 AM ET
    $SAGA
    Blank Checks
    Finance

    $SAGA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Gld Sponsor Member, Llc

    3 - Sagaliam Acquisition Corp (0001855351) (Issuer)

    5/11/23 1:10:06 PM ET
    $SAGA
    Blank Checks
    Finance

    $SAGA
    SEC Filings

    View All

    SEC Form 25-NSE filed by Sagaliam Acquisition Corp.

    25-NSE - Sagaliam Acquisition Corp (0001855351) (Subject)

    4/9/24 10:30:08 AM ET
    $SAGA
    Blank Checks
    Finance

    Sagaliam Acquisition Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Financial Statements and Exhibits

    8-K - Sagaliam Acquisition Corp (0001855351) (Filer)

    3/7/24 9:38:34 AM ET
    $SAGA
    Blank Checks
    Finance

    SEC Form 10-Q filed by Sagaliam Acquisition Corp.

    10-Q - Sagaliam Acquisition Corp (0001855351) (Filer)

    3/6/24 9:45:42 PM ET
    $SAGA
    Blank Checks
    Finance

    $SAGA
    Leadership Updates

    Live Leadership Updates

    View All

    SAGALIAM ACQUISITION CORP. ANNOUNCES RECEIPT OF NASDAQ LISTING DELINQUENCY LETTER AND APPOINTMENT OF INDEPENDENT DIRECTORS

    New York, NY, July 28, 2023 (GLOBE NEWSWIRE) -- Sagaliam Acquisition Corp. (NASDAQ: "SAGAU", "SAGA", "SAGAR") ("we", "us", "our", or the "Company") announced today that it received a delinquency notification letter ("Notice") from the Listing Qualifications staff of the Nasdaq Stock Market LLC ("Nasdaq") on July 25, 2023 due to the Company's non-compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company's failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2023 (the "Form 10-Q"). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commissio

    7/28/23 5:00:00 PM ET
    $SAGA
    Blank Checks
    Finance

    SAGALIAM ACQUISITION CORP. ANNOUNCES RESIGNATION OF THOMAS W. NEUKRANZ AS CHIEF FINANCIAL OFFICER AND DIRECTOR

    New York, NY, May 11, 2023 (GLOBE NEWSWIRE) -- Sagaliam Acquisition Corp. (NASDAQ: "SAGAU", "SAGA", "SAGAR") ("we", "us", "our", or the "Company") announced today that Thomas W. Neukranz, its Chief Financial Officer and member of its Board of Directors had resigned effective May 7, 2023. There were no disagreements between the Company and Mr. Neukranz on any matter related to the Company's operations, financial reporting, policies or practices. About Sagaliam Acquisition Corp. We are a blank check company incorporated under the laws of the State of Delaware on March 31, 2021 for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganizati

    5/11/23 1:01:00 PM ET
    $SAGA
    Blank Checks
    Finance

    $SAGA
    Financials

    Live finance-specific insights

    View All

    Sagaliam Acquisition Corp. Announces Novation Agreement with Enzolytics, Inc.

    NEW YORK, NY / ACCESSWIRE / April 26, 2024 / Sagaliam Acquisition Corp. ("SAGAU", "SAGA", SAGAR") (the "Company") announced that Sagaliam entered into a Novation Agreement with Enzolytics, Inc. (OTC:ENZC), Biogenysis, Inc. (BGEN), and Virogentics, Inc. (VIRO) (together the "Parties"). ​Under this restructured agreement SAGA retains 100% ownership of VIRO, ITV-1, the nutraceutical products and license along with VIRO's other assets. This agreement transferred ownership of Biogenysis, Inc. ("BGEN") and it's IP, patents and associated asset being developed back to ENZC in exchange for a reduction of the price from $450,000,000 to $290,000,000 with the dividend of the purchase shares to come dir

    4/26/24 8:00:00 AM ET
    $SAGA
    Blank Checks
    Finance

    Enzolytics, Inc. Files Amended December 31, 2022 OTC Report with Audited Financials and Unaudited September 30, 2023 Quarterly Disclosure

    Provides Updates on SAGA Transaction and on Virogentics, Inc. and Biogenysis, Inc. ProgressALLEN, TX / ACCESSWIRE / November 20, 2023 / Enzolytics, Inc. (OTC:ENZC) (https://enzolytics.com/"https://enzolytics.com/). Enzolytics, Inc. (the "Company") filed an amended December 31, 2022 OTC Annual Report and its delinquent September 30, 2023 OTC quarterly disclosure. The purpose of the amended OTC Annual Report filed today is to include the audited financial statements for December 31, 2022 and 2021. As part of the recently completed sale of the two operating subsidiaries, Virogenetics, Inc. ("VIRO") and Biogenysis, Inc. ("BGEN"), to Sagaliam Acquisition Corp. (NASDAQ:SAGA)("SAGA") post-closing d

    11/20/23 9:10:00 AM ET
    $SAGA
    Blank Checks
    Finance

    $SAGA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Sagaliam Acquisition Corp. (Amendment)

    SC 13G/A - Sagaliam Acquisition Corp (0001855351) (Subject)

    2/14/24 1:49:11 PM ET
    $SAGA
    Blank Checks
    Finance

    SEC Form SC 13G filed by Sagaliam Acquisition Corp.

    SC 13G - Sagaliam Acquisition Corp (0001855351) (Subject)

    2/14/24 12:16:06 PM ET
    $SAGA
    Blank Checks
    Finance

    SEC Form SC 13D filed by Sagaliam Acquisition Corp.

    SC 13D - Sagaliam Acquisition Corp (0001855351) (Subject)

    5/11/23 1:08:27 PM ET
    $SAGA
    Blank Checks
    Finance